PreludeDx™ to Present DCISionRT® Precision Medicine Study Results During Oral Scientific Session at ASTRO 2021 Annual Meeting

LAGUNA HILLS, Calif.: LAGUNA HILLS, Calif., Oct. 19, 2021 /PRNewswire/ -- Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, announced today selection for an oral scientific session presentation at the American Society of Radiation Oncology (ASTRO) 63rd Annual Meeting. Results demonstrating the clinical...

Click to view original post